Harlow John B. Jr. bought 17,800 shares of Larimar Therapeutics, Inc. at $2.80 for $49.9k on Nov 11, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
President and COO
President and COO
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$49,918.32Shares × reported price
Shares traded
17,800Common Stock
Price per share
$2.80Reported price. Read footnotes for ranges.
% of reported position traded
35.6%This security and ownership context
Holdings after
67,800Direct
Trade date
Nov 11, 2026Buy
Filed
Nov 12, 2026, 6:00 PM ET1-day reporting delay
Accession
0001193125-26-458845Code P · Transaction 399704
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 50,000 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

LRMR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LRMR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +2.4%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.7295 to $2.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.